Coldstream Capital Management Inc. Has $2.05 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Coldstream Capital Management Inc. increased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 24.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,287 shares of the biopharmaceutical company's stock after purchasing an additional 7,154 shares during the quarter. Coldstream Capital Management Inc.'s holdings in Bristol-Myers Squibb were worth $2,052,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BMY. Truist Financial Corp increased its position in Bristol-Myers Squibb by 3.9% in the 4th quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock valued at $90,335,000 after buying an additional 60,365 shares in the last quarter. Contravisory Investment Management Inc. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $488,000. Inspire Trust Co. N.A. lifted its stake in Bristol-Myers Squibb by 39.0% in the third quarter. Inspire Trust Co. N.A. now owns 103,500 shares of the biopharmaceutical company's stock valued at $5,355,000 after purchasing an additional 29,044 shares during the last quarter. Versant Capital Management Inc increased its holdings in Bristol-Myers Squibb by 14.0% in the 4th quarter. Versant Capital Management Inc now owns 78,690 shares of the biopharmaceutical company's stock worth $4,451,000 after acquiring an additional 9,692 shares during the last quarter. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $474,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Down 1.7 %

NYSE BMY opened at $47.86 on Monday. The stock's 50-day moving average price is $56.37 and its 200-day moving average price is $56.53. The company has a market capitalization of $97.38 billion, a P/E ratio of -10.83, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.55 by $0.25. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. During the same period in the prior year, the business posted ($4.40) earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.18%. Bristol-Myers Squibb's payout ratio is 92.88%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BMY shares. Jefferies Financial Group dropped their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Finally, Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 1,823 shares of the business's stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.09% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.